Empagliflozin significantly lowered LVMi, systolic blood pressure, and diastolic blood pressure in patients with CAD and type 2 diabetes.
Read More »Ethnicity Can Affect Risk for Diabetes Complications
A diabetes patient’s risk for chronic kidney disease or cardiovascular disease can be impacted by various factors, including ethnic background.
Read More »Empagliflozin Benefit in Heart Failure, With or Without Diabetes
Studies of empagliflozin and dapagliflozin have shown to reduce cardiovascular risk, indicating a class effect for heart failure patients.
Read More »Using SGLT-2 Inhibitors to Significantly Reduce AFib
Diabetes causes metabolic changes that promote oxidative stress within the heart, resulting in changes that can impede its electrical signaling.
Read More »PCOS Increases Risk For CVD
Insulin resistance and weight gain are common with PCOS and impact multiple CVD risk factors.
Read More »The Role of Dapagliflozin in Patients with Type 2 Diabetes and Atrial Fibrillation
A post hoc analysis of the DECLARE-TIMI 58 trial may provide a new compelling indication for dapagliflozin.
Read More »Major Reduction in Risk of Heart Attacks in Patients with Diabetes
Initiating the right medications upon diabetes diagnosis can help mitigate heart attack risk.
Read More »Real-World Data on the Benefit of Sodium Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Risk
SGLT2 inhibitors compared to DPP-4 inhibitors: which showed a favorable effect on MACE?
Read More »Cardiovascular Outcomes of Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease
Finerenone, which treats CKD, may also help to reduce cardiac failure in type 2.
Read More »Cognitive Decline a Result of Diabetes and Hypertension
The CARDIA study explored the link to the decline in cognitive abilities in diseases like Alzheimer's and Parkinson's in middle-aged populations.
Read More »